CD274 and cancer: Nevertheless, an increasing list of ICIs has been approved for treatment of more types of cancer, and recently a new subclass of ICIs (anti PDL1 mAbs) was approved; in addition, new, more complicated therapeutic protocols, including combinations of ICI therapies are currently being used, while multiple lines of ICI treatment (sequential treatment) are being administered in patients with refractory cancer.